Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1998-08-11
2000-09-12
Witz, Jean C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
424641, 514169, 514170, A61K 3578
Patent
active
061174297
ABSTRACT:
A method for reducing potential adverse effects of androgenic testosterone precursors by interfering with production or action of testosterone and estrogen metabolites by nutrient combinations is described. Although androgenic testosterone precursors themselves have little or no toxicity, there is the potential for their metabolites, estradiol and dihydrotestosterone, to enhance or cause hormone-responsive illnesses such as breast or prostatic cancer, benign prostatic hyperplasia, or hirsutism or acne in women. The use of the invented nutrient combinations reduces the formation or action of estradiol and dihydrotestosterone, thereby reducing potential adverse effects from increased production of these hormones following androgenic testosterone precursor administration. This may be accomplished without negating the effects of testosterone on muscle anabolism. The nutrient combinations include androstenedione, DHEA, pregnenolone, androstenediols, norandrostenedione and norandrostenediols, and natural products which reduce estrogen effects in the estrogen-responsive tissues, and substances to reduce formation of dihydrotestosterone from testosterone in prostate tissue.
REFERENCES:
patent: 3647829 (1972-03-01), Kruger
patent: 4014988 (1977-03-01), Pharriss et al.
patent: 4016270 (1977-04-01), Pharriss et al.
patent: 4054651 (1977-10-01), Benson et al.
patent: 4100026 (1978-07-01), Weber et al.
patent: 4100027 (1978-07-01), Weber et al.
patent: 4170518 (1979-10-01), Weber et al.
patent: 4235893 (1980-11-01), Brodie et al.
patent: 4331657 (1982-05-01), Cox et al.
patent: 4457914 (1984-07-01), Cox et al.
patent: 4474701 (1984-10-01), Teichmuller et al.
patent: 4500523 (1985-02-01), Nathanielsz
patent: 4749567 (1988-06-01), McNatty et al.
patent: 4920115 (1990-04-01), Nestler et al.
patent: 4946701 (1990-08-01), Tsai et al.
patent: 5028600 (1991-07-01), Jeppsson
patent: 5116828 (1992-05-01), Miura et al.
patent: 5166200 (1992-11-01), Fujise et al.
patent: 5183815 (1993-02-01), Saari et al.
patent: 5206008 (1993-04-01), Loria
patent: 5227375 (1993-07-01), Labrie et al.
patent: 5277907 (1994-01-01), Loria
patent: 5296481 (1994-03-01), Partridge et al.
patent: 5372822 (1994-12-01), Fahim
patent: 5387583 (1995-02-01), Loria
patent: 5391776 (1995-02-01), Ueno et al.
patent: 5418145 (1995-05-01), Webber et al.
patent: 5420120 (1995-05-01), Boltralink
patent: 5424463 (1995-06-01), Lardy et al.
patent: 5446070 (1995-08-01), Mantelle
patent: 5461042 (1995-10-01), Loria
patent: 5489581 (1996-02-01), Daynes et al.
patent: 5506223 (1996-04-01), Lardy et al.
patent: 5516649 (1996-05-01), Weber et al.
patent: 5527552 (1996-06-01), Todd, Jr.
patent: 5532230 (1996-07-01), Daynes et al.
patent: 5536714 (1996-07-01), Kojima et al.
patent: 5545634 (1996-08-01), Labrie
patent: 5565444 (1996-10-01), Mizushima et al.
patent: 5578588 (1996-11-01), Mattern et al.
patent: 5583126 (1996-12-01), Daynes et al.
patent: 5583128 (1996-12-01), Bhatnagar
patent: 5585371 (1996-12-01), Lardy
patent: 5587369 (1996-12-01), Daynes et al.
patent: 5635496 (1997-06-01), Daynes et al.
patent: 5641768 (1997-06-01), Loria
patent: 5719197 (1998-02-01), Kanios et al.
patent: 5728688 (1998-03-01), Labrie
patent: 5776923 (1998-07-01), Labrie
patent: 5780086 (1998-07-01), Kirksey et al.
patent: 5780460 (1998-07-01), Labrie
patent: 5798347 (1998-08-01), Labrie
patent: 5804576 (1998-09-01), Schwartz et al.
patent: 5807849 (1998-09-01), Labrie
patent: 5824671 (1998-10-01), Labrie
patent: 5837700 (1998-11-01), Labrie
patent: 5843932 (1998-12-01), Labrie
patent: 5854229 (1998-12-01), Labrie
patent: 5872114 (1999-02-01), Labrie
Larue, J.P., Morfin, R.F., Charles, J.F. Le zinc dans la prostate humaine. Journal d'Urologie, 91, No. 7, (1985) pp. 463-468. [English Abstract].
Habenicht, Ursula-F, Schwarz, Klaus, Schweikert, Hans-U., Neumann, Friedmund, El Etreby, M. Fathy. Development of a Model for the Induction of Estrogen-Related Prostatic Hyperplasia in the Dog and its Response to the Aromatase Inhibitor 4-Hydroxy-4-Androstene-3, 17-Dione: Preliminary Results. The Prostate 8: (1986) pp. 181-194.
Habenicht, Ursula-F., El Etreby, M. Fathy. Synergic Inhibitory Effects of the Aromatase Inhibitor 1-Methyl-Androsta-1, 4-Diene-3, 17-Dione and the Antiandrogen Cyproterone Acetate on Androstenedione-Induced Hyperplastic Effects in the Prostates of Castrated Dogs. The Prostate 11: (1987) pp. 133-143.
Schaeffer, Hans-Jorg, Sirotkin, Alexander V. The Release of Insulin-like Growth Factor-I Luteinized Human Granulosa Cells in Vitro: Regulation by Growth Hormone, Oxytocin, Steroids and cAMP-dependent Intracellular Mechanisms. Experimental and Clinical Endocrinology & Diabetes. 103 (1995) pp. 361-366.
Mastrogiacomo, I, Bonanni, G., Menegazzo, E., Santarossa, C., Pagani, E., Gennarelli, M., Angelini, C. Clinical and Hormonal Aspects of Male Hypogonadism in Myotonic Dystrophy. Italian Journal of Neurological Science, 17: (1996) pp. 59-65.
Bassir, O., Odebiyi, O. Male Virilising Substances in Some Nigerian Medicinal Preparations--Androgenic Steriods. W.A. Journal of Biological and Applied Chemistry. vol. 19, No. 2, (1976). pp. 25-29. DHEA by USA Nutritionals, Drug Store News, p. 39, Jan. 1997.
Yen, S.S.C. et al., Annals of the New York Academy of Sciences, vol. 774, p. 128-142, Dec. 1995.
Arif Adimoella, F.X. et al., International J. of Andrology, vol. 20(1), p. 39, abstract #153, 1997.
Nippon Zoki Pharmaceutical, Oct. 26, 1990.
Winkler, et al., Nov. 11, 1993.
Alen, M., Pakarinen, A., Hakkinen, K. and Komi, P.V. Responses of Serum Androgenic-Anabolic and Catabolic Hormones to Prolonged Strength Training. Int. J. Sports Med. vol. 9 (1988). pp. 229-233.
Abrahamsson, G., Janson, P.O., and Kullander, S. Steroid Release From Two Human Epithelial Ovarian Tumors: Evidence For An Intrinsic Production in Vitro. Gynecologic Oncology, vol. 64 (1997), pp. 64, 99-104.
Auzeby, A., Bogdan, A., and Touitou, Y.. An Alternate Pathway to Androstenedione Syntheses by Human Adrenals: Evidence of a Balance in 11.beta.-Hydroxylase and 17,20-Lyase Activities Leading to Androstenedione. Journal of Clinical Endroclinology and Metabolism, vol. 80, No. 5 (1995), pp. 1706-1711.
Barrett-Connor, Elizabeth, Garland,Cedric, McPhillips, Janice B., Khaw, Kay-Tee, and Wingard, Deborah L. Cancer Research vol. 50 (1990), pp. 169-173.
Bartsch, Wilfred, Klein, Hartmut, Sturenburg, Hans-Jorg, and Vorgt, Klass-Dieter. Metabolism of Androgens in Human Benign Prostatic Hyperplasia: Aromatase and its Inhibition. Steriod Biochem, vol. 27, No. 1-3 (1987), pp. 557-564.
Begin, D., Luthy, I.A., and Labrie, F. Adrenal Precursor C.sup.19 Steriods are Potent Stimulators of Growth of Androgen-Sensitive Mouse Mammary Carcinoma Shionogi Cells in Vitro. Molecular and Cellular Endocrinology, vol. 58 (1988), pp. 213-219.
Belisle, Serge, Lehoux, Jean-Guy, and Brault, Jacques. The Metabolism of Androstenedione in Human Pregnancy: The Use of Constant Infusion of Unlabeled Steriod to Assess Its Metabolic Clearance Rate, Its Production Rate, and Its Conversion into Androgens and Estrogens. American Journal of Obstetrics and Gynecology, vol. 136, No. 8 (1980), pp. 1030-1035.
Belisle, Serge, Osathanondh, Rapin, and Tulchinsky, Dan. The Effect of Constant Infusion of Unlabeled Dehydroepiandrosterone Sulfate on Maternal Plasma Androgens and Estrogens. Journal of Clinical Endocrinology and Metobolism, vol. 45, No. 3 (1977), pp. 544-550.
Brodie, A.M.H., Son, C., King, D.A., Meyer, K.M. and Inkster, S.E. Lack of Evidence for Aromatase in Humkan Prostatic Tissues: Effects of 4-Hydroxyandrostenedione and Other Inhibitors on Androgen Metabolism. Cancer Research vol. 49 (1989), pp. 6550-6555.
Bulun, Serdar E., Simpson, Evan R., and Word R. Ann. Expression of the CYP 19 Gene and Its Propduct Aromatase Cytochrome P450 in Human Uterine Leiomyoma Tissues and Cells in Culture. Journal of Clinical Endocrinology and Mebabolism, vol. 78, No. 3 (1994), pp. 736-743.
Cauley, Jane A., Gutai, James P., Kuller, Lewis H., LeDonne, Dorothea, and Powell, John G. The Epidemiology of Serum Sex Hormones in Postmenopausal Women. American Journal of E
Weider Nutrition International, Inc
Witz Jean C.
LandOfFree
Compositions and treatments for reducing potential unwanted side does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and treatments for reducing potential unwanted side, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and treatments for reducing potential unwanted side will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-93150